Neurocrine Biosciences

Neurocrine Biosciences Inc is assigned a 2-star quantitative star rating, illustrating our stance that this share class is a somewhat unattractive choice, and investors should look elsewhere for more fruitful opportunities. The stock currently trades at a 11% premium over our quantitative fair value estimate of $127.37 per share; however, this estimate should be taken with a pinch of salt due to its medium uncertainty rating.

The company's valuation metrics undermine our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's enterprise value to market value ratio of 1.0 lies in the bottom 45% compared with peers globally. The market value of equity makes up a large fraction of enterprise value, indicating that shares have sharply risen, or that the company has a "lazy" balance sheet that is underleveraged. We believe this is a sign that shares could be overvalued.

The company's unfavorable dividend structure is an additional cause for concern. Dividends represent a stable form of future cash flows returned to shareholders, and low dividend payments can increase the perceived risk of a business. The firm's forward dividend yield of 0%, for example, falls in the bottom 30% globally. This could imply a planned dividend cut or relatively high share price, which further promotes our unfavorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

The narrow moat rating for this company indicates investors can expect it to generate 10 years or more of excess returns on capital due to its respectable competitive advantages. Its moat is bolstered by its strong financial health, which indicates low near-term bankruptcy risk.